Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer

British Journal of Cancer

Volumn 77, Issue 11, 1998, Pages 1950-1956

  O'Byrne, K J ^a   Koukourakis, M I ^a   Saunders, M P ^a   Salisbury, A J ^a   Isaacs, R ^a   Varcoe, S ^a   Taylor, M ^a   Ganesan, T S ^a   Harris, A L ^a   Talbot, D C ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

5 Fluorouracil; Breast cancer; Cyclophosphamide; Infusion; Methotrexate

Indexed keywords

AMINOGLUTETHIMIDE; BATIMASTAT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; HYDROCORTISONE; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; PREDNIMUSTINE; TAMOXIFEN; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DOSE CALCULATION; FATIGUE; FEMALE; FEVER; HUMAN; INFUSION PUMP; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0031749830     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.323     Document Type: Article

References (34)

1. Bern MM, Lokich JJ, Wallach SR, Bothe Jr A, Benotti PN, Arkin CF, Greco FA, Huberman M and Moore C (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 112: 423-428
2. Bonnadona G and Valagusa P (1985) CMF based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5: 95-115
3. Brandi M, De-Mitrio A, Ditonno P, Catino A, Lorusso V and DeLena M (1994) Oral versus intravenous CMF in metastatic breast cancer: A randomised study. Int J Oncol 4: 559-565
4. Brown-Smith JK, Stoner MH and Barley Z (1990) Tunneled catheter thrombosis: factors related to incidence. Oncol Nursing Forum 17: 543-549
5. Capri G, Tarenzi E, Fulfaro Fand Gianni L (1996) The role of taxanes in the treatment of breast cancer. Semin Oncol 23 (1 suppl. 2): 68-75
6. Christophidis N, Vajda FJE, Lucas I, Drummer O, Moon WJ and Louis WJ (1978) Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet 3: 330-336
7. DeBrujn EA, Driessen OM and Hermans J (1991) The CMF regimen. Toxicity patterns following stepwise combinations of cyclophosphamide, methotrexate and fluorouracil. Int J Cancer 48: 67-72
8. Eastridge BJ and Lefor AT (1995) Complications of indwelling venous access devices in cancer patients. J Clin Oncol 13: 233-238
9. Engelsman E, Klijn JCM, Rubens RD, Wildiers J, Beex LVAM, Nooij MA, Rotmensz N and Sylvester R (1991) 'Classical CMF' versus a 3-weekly intravenous CMF schedule in post-menopausal patients with advanced breast cancer. Eur J Cancer 27: 966-970
10. Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S and Stephens R (1990) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest new Drugs 8: 57-63
11. Falkson G, Tormey DC, Carey P, Witte R and Falkson HC (1991) Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer. Eur J Cancer 27: 973-977
12. Greene D, Nail LM, Fieler VK, Dudgeon D and Jones LS (1994) A comparison of patient-reported side-effects among three chemotherapy regimens for breast cancer. Cancer Pract 2: 57-62
13. Hansen R, Quebbeman E, Beatty P, Ritch P, Anderson T, Jenkins D, Frick J and Ausman R (1987) Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat 10: 145-149
14. Hansen RM (1991) 5-fluorouracil by protracted venous infusion: a review of recent clinical studies. Cancer Invest 9: 637-642
15. Hayes DF, Henderson IC and Shapiro C (1995) Treatment of metastatic breast cancer: present and future prospects. Semin Oncol 22 (Suppl. 5): 5-21
16. Heggie GD, Sommadossi JP, Cross DS, Hasler WJ and Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma. urine and bile. Cancer Res 47: 2203-2206
17. Henderson IC, Hayes DF and Gelman R (1988) Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 6: 1501-1515
18. Huan S, Pazdur R, Singhakowinta A, Bohumil S and Vaitkevicius VK (1989) Low dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma. Cancer 63: 419-422
19. Jabboury K, Holmes FA and Hortobagyi G (1989) 5-fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 64: 793-797
20. Jones AL, Smith IE, O'Brien ME, Talbot D, Walsh G, Ramage F, Robertshaw H and Ashley S (1994) Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol 12: 1259-1256
21. Lokich J, Bothe A, Fine N and Perri J (1981) Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48: 2565-2568
22. Lokich J, Fine N, Perri J and Bothe A (1983) Protracted ambulatory venous infusion of 5-fluorouracil. Am J Clin Oncol Cancer Clin Trial 6: 103-107
23. Luck HJ, Thomssen C, Dubois A, Lisboa BW, Untch M, Kuhnle H, Konecny G, Janicke F, Meerpohl HG, Lindner C, Hecker D and Diergarten K (1996) Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Semin Oncol 23 (1 suppl. 1): 33-36
24. Mackay J, Cameron DA, Gardiner J, Leonard T, Lee LE, Leonard RCF (1996) A pilot study of infusional CMF (CMF-inf): Active and well tolerated in breast cancer. Ann Oncol 7: 409-411
25. McDermott BJ, Vanderbers HW and Murphy RF (1982) Non-linear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Cancer Chemother Pharmacol 9: 173-179
26. Ng JSY, Cameron DA, Lee L, Dixon JM and Leonard RCF (1994) Infusional 5-fluorouracil given as a single agent in relapsed breast cancer: its activity and toxicity. Breast 3: 87-89
27. Pfeiffer P, Cold S and Rose C (1992) Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use? Acta Oncol 31: 219-224
28. Shapiro CL, Gelman RS, Hayes DF, Osteen R, Obando A, Canellos GP, Frei III, E and Henderson IC (1993) Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. J Natl Cancer Inst 85: 812-817
29. Smith IE and Powles TJ (1993) MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the management of metastatic breast cancer. Oncology 50 (Suppl. 1): 9-15
30. Smith IE, Jones AL, O'Brien ME, McKinna JA, Sacks N and Baum M (1993) Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer 29: 1796-1799
31. Smith IE, Walsh G, Jones AL, Prendiville J, Johnston S, Gusterson B, Ramage F, Robertshaw H, Sacks N, Ebbs S, McKinna JA and Baum M (1995) High complete remission rates with primary neo-adjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13: 424-429
32. Sotos GA, Grojan L and Allegra CJ (1994) Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 20: 11-19
33. Spicer DV, Ardalan B, Daniels JR, Silbermann H and Johnson K (1988) Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res 48: 459-461
34. Tannock JF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, Mayers C, Perrault D and Sutherland H (1988) A randomised trial of two dose levels of CMF chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6: 1377-1387